Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_22
Snippet: Real-world data for treatment of COVID-19 with LPV/r are emerging. Young et al [30] reported outcomes of the first 18 patients infected with SARS-CoV-2 in Singapore, 5 of whom received LPV/r monotherapy. Three patients had reduction in oxygen requirements after treatment initiation; 2 deteriorated to respiratory failure. Two of 5 patients (40%) experienced clearance of viral shedding on treatment, and 4 of 5 (80%) experienced adverse events that .....
Document: Real-world data for treatment of COVID-19 with LPV/r are emerging. Young et al [30] reported outcomes of the first 18 patients infected with SARS-CoV-2 in Singapore, 5 of whom received LPV/r monotherapy. Three patients had reduction in oxygen requirements after treatment initiation; 2 deteriorated to respiratory failure. Two of 5 patients (40%) experienced clearance of viral shedding on treatment, and 4 of 5 (80%) experienced adverse events that precluded completion of the planned 14-day treatment course. Other published case reports or case series from Korea and China comprising 6 total patients describe decreased viral load and clinical improvement after LPV/r initiation. These data are difficult to interpret in light of concomitant drug therapies, varied time points of therapy initiation, heterogeneous severity of illness amongst patients, and the lack of comparator treatments [31] [32] [33] . Finally, early reports from Wuhan have described some patients receiving LPV/r in addition to other therapies (including corticosteroids), but clinical outcomes and adverse events are either not described or not delineated by treatment group [34] [35] [36] .
Search related documents:
Co phrase search for related documents- adverse event and clinical improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- adverse event and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and comparator treatment: 1, 2
- adverse event and drug therapy: 1, 2, 3, 4, 5, 6
- adverse event and early report: 1, 2
- adverse event clinical outcome and clinical outcome: 1
- case series and clinical improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case series and clinical improvement decrease viral load: 1
- case series and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case series and decrease viral load: 1, 2
- case series and drug therapy: 1, 2, 3, 4, 5, 6
- case series and early report: 1, 2, 3, 4, 5, 6, 7
- clinical improvement and comparator treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical improvement and decrease viral load: 1, 2, 3, 4, 5
- clinical improvement and drug therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- clinical improvement and early report: 1, 2
- clinical improvement decrease viral load and decrease viral load: 1
- clinical outcome and comparator treatment: 1, 2, 3
- clinical outcome and decrease viral load: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date